Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07H21/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/185907HERBICIDE TOLERANT PLANTS AND PRODUCTION AND DETECTION OF SAME
WO 17.09.2020
Int.Class A01H 1/04
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
HNEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
1Processes for modifying genotypes
04Processes of selection
Appl.No PCT/US2020/022118 Applicant COLORADO STATE UNIVERSITY RESEARCH FOUNDATION Inventor GAINES, Todd
The present invention refers to a plant or plant part comprising a polynucleotide encoding an herbicide tolerant IAA2 polypeptide having a deleted or disrupted degron tail region, the expression of said polynucleotide confers to the plant or plant part tolerance to synthetic auxin herbicides, such as 2,4-D. The present invention relates to methods and plants and that have a deleted or disrupted degron tail region of the IAA2 protein obtained by gene editing, transformation, mutagenesis, breeding, and the like.
2.WO/2020/181825NUCLEIC ACID EXTRACTION APPARATUS
WO 17.09.2020
Int.Class C12M 1/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
Appl.No PCT/CN2019/119366 Applicant CHEN, Hui Inventor CHEN, Hui
Disclosed is a nucleic acid extraction apparatus. The nucleic acid extraction apparatus comprises a workbench having a table top, and further comprises a sliding seat, a sample rack, a reagent strip rack, a pipetting table, a piston assembly and a suction assembly. The nucleic acid extraction apparatus comprises the sliding seat and the pipetting table, the sample rack and the reagent strip rack are arranged on the sliding seat, the piston assembly and the suction assembly are respectively arranged on the pipetting table, the sample rack is provided with sample holes, the reagent strip rack is provided with accommodation slots, the number of accommodation slots corresponds to that of the sample holes on a one-to-one basis, and when reagent strips are respectively accommodated in the accommodation slots, a first suction head hole, second suction head holes and various reagent holes in each reagent strip respectively correspond to the corresponding sample holes, such that the loading of a suction head assembly and suction heads and operations such as suction, injection and mixing of a sample and various reagents can be realized by means of a vertical movement, relative to the sliding seat, of the pipetting table and a horizontal movement, relative to the pipetting table, of the sliding seat, thereby realizing the automated operation of nucleic acid extraction.
3.WO/2020/186124MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER
WO 17.09.2020
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/US2020/022519 Applicant THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK Inventor JU, Jingfang
The present disclosure provides modified microRNA nucleic acid compositions that have one or more cytosine and/or uracil bases replaced with gemcitabine or a 5-halouracil, respectively. More specifically, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule increases the ability of the microRNA to inhibit cancer progression and tumorigenesis. In addition, the present disclosure reveals that the replacement of cytosine nucleotides within a microRNA nucleotide sequence with a gemcitabine molecule and replacement of uracil bases with 5-halouracil increases the ability of the microRNA to inhibit cancer development. As such, the present disclosure provides various modified nucleic acid (e.g., microRNA) compositions having gemcitabine molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.
4.WO/2020/185562NOVEL ANTIMICROBIAL LANTIBIOTIC PEPTIDE AND USES THEREOF
WO 17.09.2020
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
Appl.No PCT/US2020/021396 Applicant FRAUNHOFER USA, INC. Inventor KARCZEWSKI, Jerzy
A novel lantibiotic peptide and a composition comprising the peptide in an antimicrobial effective amount are provided. A method for preparing the composition from a medium into which host cells produce the peptide is also provided. A method of inhibiting growth of microbial cells, killing microbial cells or treating a subject infected by microbial cells, comprising administering to the microbial cells or the subject an effective amount of the peptide or the composition is further provided. Where the microbial cells are on a surface, the method may further comprise administering the peptide or the composition to the surface.
5.WO/2020/185781MICRORNA REGULATORY NETWORK AS BIOMARKERS OF SEIZURE IN PATIENTS WITH SPONTANEOUS INTRACEREBRAL HEMORRHAGE
WO 17.09.2020
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/US2020/021896 Applicant OCHSNER HEALTH SYSTEM Inventor IWUCHUKWU, Ifeanyi
A method of predicting seizure in a subject that has had an intracerebral hemorrhage, comprising: measuring at least one of miRNA listed in Tables 1A, 1B, 1C and 6-8 in a sample obtained from a subject, wherein the at least one of miRNA comprises at least one of hsa-miR-4325, hsa-miR-181a-5p, hsa-miR-1180-3p, and miR-4317 wherein down regulation of hsa-miR-4325 or hsa-miR-4317 relative to a control indicates the subject will exhibit seizures and wherein upregulation of hsa-miR-181a-5p and hsa-miR-1180-3p, relative to a control indicates the subject will exhibit seizures.
6.WO/2020/184799OLIGONUCLEOTIDE HAVING ANTI-INFLAMMATORY ACTIVITY
WO 17.09.2020
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/KR2019/013184 Applicant PARK, Donghwi Inventor PARK, Donghwi
The present invention pertains to: an oligonucleotide having an anti-inflammatory activity; and a pharmaceutical composition containing same for preventing or treating inflammatory diseases.
7.WO/2020/183238REVERSIBLE COATING OF CHITOSAN-NUCLEIC ACID NANOPARTICLES AND METHODS OF THEIR USE
WO 17.09.2020
Int.Class A61K 47/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Appl.No PCT/IB2020/000175 Applicant ENGENE, INC. Inventor PANICKER, Rajesh Krishnan Gopalakrishna
Chitosan-nucleic acid polyplex compositions containing a reversibly bound polymer coat comprising linear block copolymers with a polyanionic anchor region and at least one polyethylene glycol tail region are described herein. In some cases, the compositions exhibit improved stability and/or mucosal diffusion as compared to uncoated particles. In some cases, the reversibly bound polymer coat does not interfere with, or enhances, transfection of target cells or tissues as compared to uncoated particles.
8.WO/2020/180886NEUROPROTECTIVE GENE THERAPY TARGETING THE AKT PATHWAY
WO 10.09.2020
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/US2020/020832 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor BENNETT, Jean
Compositions and methods for the treatment of retinal degeneration are provided. In one aspect, provided herein is adeno-associated virus (AAV) vector comprising an AAV capsid having encapsidated therein a vector genome comprising AAV inverted terminal repeat (ITR) sequences, a human protein kinase B (AKT) coding sequence, and expression control sequences that direct expression of AKT in a host cell.
9.WO/2020/178165TERTIARY AMINE SUBSTITUTED COUMARIN COMPOUNDS AND THEIR USES AS FLUORESCENT LABELS
WO 10.09.2020
Int.Class C07D 405/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/EP2020/055257 Applicant ILLUMINA CAMBRIDGE LIMITED Inventor ROMANOV, Nikolai
The present application relates to tertiary amine substituted coumarin derivatives of formula (I) and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
10.WO/2020/180645ELECTROCHEMILUMINESCENT LABELED PROBES FOR USE IN IMMUNOASSAY METHODS, METHODS USING SUCH AND KITS COMPRISING SAME
WO 10.09.2020
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/US2020/020288 Applicant MESO SCALE TECHNOLOGIES, LLC. Inventor KENTEN, John
The present invention is directed to assay methods and compounds and kits used in such assays.